Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome

Hahn, Susanne; Kuehnel, Werner; Tan, Susanne; Kramer, Karen A.; Schmidt, M; Roesler, S.; Kimmig, Rainer; Mann, Klaus; Janßen, Onno E.

doi:10.1515/cclm.2007.031

Cited by 65 publications

(44 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An SHBG cutoff of 37 nmol/L (AURC 0.875, sensitivity of 87.5%, specificity of 86.8%) was the best parameter for the diagnosis of PCOS, and FAI, calculated FT, and DHEAS were also considered adequate measures for the diagnosis of PCOS in a study [30]. In Hahn's study [31], the highest AURC was found for bioavailable testosterone (0.852) followed by FAI (0.847) and free testosterone (0.837). In the present study, AMH was the best parameter for the diagnosis of PCOS, though total testosterone with a cutoff of 1.40 nmol/L (AURC 0.773, sensitivity 63.2%, specificity 83.0%) was also adequate.…”

Section: Discussionmentioning

confidence: 95%

“…In Lin's study [8], PCOS-risk cases with one of three PCOS components were classified into non-PCOS group, while these same PCOS-risk cases were excluded from the control group in Pigny [25] and in our study. There were a few studies that performed ROC curve analysis for the cutoff of biochemical parameters of hyperandrogenism other than AMH for the diagnosis of PCOS [30,31]. An SHBG cutoff of 37 nmol/L (AURC 0.875, sensitivity of 87.5%, specificity of 86.8%) was the best parameter for the diagnosis of PCOS, and FAI, calculated FT, and DHEAS were also considered adequate measures for the diagnosis of PCOS in a study [30].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Differences of the association of anti-Müllerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome

et al. 2012

View full text Add to dashboard Cite

POLYCYSTIC OVARY SYNDROME (PCOS) is one of the most common endocrinological problems in women. In addition to chronic oligo-anovulation, the main features of the PCOS include elevated levels of circulating androgens and/or clinical hyperandrogenism, polycystic ovary morphology, altered gonadotropin secretion, insulin resistance and/or compensatory hyperinsulinemia often associated with obesity [1]. Women affected by PCOS also show a higher risk of type 2 diabetes, dyslipidemia, hypertension and cardiovascular diseases [2][3][4].Differences of the association of anti-Müllerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome Abstract. The aim of the present study was to compare the associations of anti-Müllerian hormone (AMH) with clinical or biochemical characteristics between women with and without polycystic ovary syndrome (PCOS). We also explored the optimal cutoff point of AMH to diagnose PCOS. A cross-sectional study was performed in 87 women diagnosed with PCOS and 53 healthy control subjects. Body mass index (BMI), indices of insulin resistance, metabolic syndrome-related variables, reproductive hormones and serum AMH were measured in all subjects. We conducted receiver operating characteristic (ROC) curve analysis to determine the cutoff of AMH for diagnosis of PCOS. Serum AMH levels were significantly (p <0.001) higher in women with PCOS after adjustment for age and BMI. AMH levels were not significantly related with obesity, indices of insulin resistance, and metabolic syndrome-related variables in both PCOS and control groups. In the control group, AMH levels showed positive correlations with total testosterone (p <0.001), free testosterone (p=0.024), and adiponectin (p=0.002), and showed negative correlations with age (p=0.010) and estradiol (E2) (p=0.012). However, only total (p=0.044) and free testosterone (p=0.012) levels showed significant positive correlations with serum AMH level in PCOS group. ROC curve analysis showed a cutoff point for AMH of 7.82 ng/mL (sensitivity 75.9%, specificity 86.8%) for diagnosis of PCOS. Differences of the association of AMH with clinical or biochemical characteristics between women with PCOS and control groups were observed. This might contribute to the pathogenesis of PCOS, although further investigation is necessary to elucidate the detailed mechanism.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

Differences of the association of anti-Müllerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Hyperandrogenism was diagnosed as biochemical when the serum testosterone level was greater than 78 ng/dl (upper limit of normal range in our laboratory) or FAI>4.97 (free androgen index is serum testosterone (ng/ dl): sex hormone-binding globulin (SHBG)mmol/ml×3.47) [15], or clinical when signs of hyperandrogenism were present during the physical exam, such as hirsutism (diagnosed with facial, abdominal, or chest hair) and/or acne. We did not use a dedicated scoring system for hirsutism, as this was not the main reason for presentation to our clinic and no therapy was implemented for this complaint.…”

Section: Methodsmentioning

confidence: 99%

Fertility biomarkers to estimate metabolic risks in women with polycystic ovary syndrome

Detti

Jeffries-Boyd

Williams

et al. 2015

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose We sought to evaluate the relationship between the polycystic ovary syndrome (PCOS)-defining characteristics and the risk of developing metabolic complications in women presenting with complaints of infertility and/or menstrual irregularities and subsequently diagnosed with PCOS. Methods This was a cross-sectional study. Women presenting with complaints of infertility and/or irregular menses and diagnosed with PCOS by the Rotterdam criteria, underwent endocrine, metabolic, and ultrasound assessment in the early follicular phase. Reproductive and metabolic parameters were included in regression analysis models with the PCOSdefining characteristics; ROC curves were calculated for the significant predictors. Results Three hundred and seventy-four women with PCOS were included in our study. Oligo-anovulation, menstrual irregularities, and hirsutism were not predictive of any of the variables. Ovarian volume, follicle count, and biochemical hyperandrogenism were predictors for hormonal, metabolic, and endometrial complications. The relationships were independent of age and body mass index. ROC curves identified lower cut-off values of the PCOS-defining characteristics to predict patients' risks of hyperinsulinemia, dyslipidemia, and glucose intolerance. Conclusions Adverse metabolic effects of PCOS are already present in women at the time they present complaining of infertility and/or irregular menses. Hyperandrogenism and ultrasound can assist in predicting the patients' concomitant metabolic abnormalities and can aid physicians in tailoring counseling for effective preventive strategies.

show abstract

“…This study measured total testosterone, SHBG, luteinizing hormone (LH), follicle-stimulating hormone (FSH), androstendione, dehydroepiandrosterone sulfate (DHEAS) and calculated the bioavailable testosterone by FAI. They found bioavailable testosterone to have a greater accuracy than the FAI, followed by free testosterone (12).…”

Section: Discussionmentioning

confidence: 99%

Markers of hyperandrogenism in South Asians with polycystic ovary syndrome

Boteju¹,

Karunarathna²,

Udayangani³

et al. 2014

Sri Lanka J. Diabetes Endocrinol. Metab.

View full text Add to dashboard Cite

show abstract

Diagnostic value of calculated testosterone indices in the assessment of polycystic ovary syndrome

Abstract: ROC analysis provided evidence that calculated testosterone indices (bioavailable testosterone, FAI, free testosterone) are useful parameters for the discrimination of PCOS patients and healthy controls.

Cited by 65 publications

References 32 publications

Differences of the association of anti-Müllerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome

Differences of the association of anti-Müllerian hormone with clinical or biochemical characteristics between women with and without polycystic ovary syndrome

Fertility biomarkers to estimate metabolic risks in women with polycystic ovary syndrome

Markers of hyperandrogenism in South Asians with polycystic ovary syndrome

Contact Info

Product

Resources

About